Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA

INTRODUCTION: Recurrent Clostridioides difficile infection (rCDI) is common and associated with considerable clinical and economic consequences. REBYOTA™ (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevention of rCDI following antibiotic treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas, Guo, Amy, Yang, Min, Cook, Erin E., Song, Wei, Yang, Danni, Wang, Qingyuan, Zhao, Angela, Bochan, Markian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220097/
https://www.ncbi.nlm.nih.gov/pubmed/37093359
http://dx.doi.org/10.1007/s12325-023-02505-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220097/
https://www.ncbi.nlm.nih.gov/pubmed/37093359
http://dx.doi.org/10.1007/s12325-023-02505-1

Ejemplares similares